GlassScriptPhysician profile
Ramona Payton
NPI 1376768838
$2,466.52
in general payments reported to CMS, 2019-2025
29 companies · $628 in 2025
The $628 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $476 · 2023: $753 · 2024: $610 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,990.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $218.78 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $206.44 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $193.85 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $182.34 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $176.30 | 2022-2023 | |
| Abbvie INC. | $165.59 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $164.35 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.13 | 2022-2025 | Jardiance |
| Abbott Laboratories | $117.22 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $111.94 | 2022-2024 | Prolia, Evenity, Repatha |
| Scynexis, INC. | $93.82 | 2022 | |
| Merck Sharp & Dohme LLC | $79.29 | 2023-2024 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $70.65 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $69.17 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $68.21 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.73 | 2025 | Caplyta |
| Dynavax Technologies Corporation | $48.01 | 2024-2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $46.06 | 2022-2024 | Farxiga |
| Sumitomo Pharma America, INC. | $43.01 | 2023-2025 | Gemtesa |
| Shield Therapeutics INC | $41.28 | 2023-2024 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.24 | 2022-2024 | Xifaxan |
| Corcept Therapeutics | $29.41 | 2024 | Korlym |
| Exact Sciences Corporation | $28.27 | 2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $20.74 | 2025 | Symbravo |
| Sanofi Pasteur INC. | $17.50 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.00 | 2023 | Quviviq |
| Amarin Pharma, INC. | $14.68 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.39 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramona Payton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.